Overview

Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies. The Company advanced program XTANDI (enzalutamide) capsules, or XTANDI, is partnered with Astellas Pharma Inc. ( Astellas). Together with Astellas, the Company is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. It also has ongoing programs with other agents in multiple different indications in early stages of research and development. The Company and Astellas also conduct the TERRAIN trial and the STRIVE trial, two randomized, double-blind Phase 2 trials evaluating enzalutamide head-to-head versus bicalutamide, the marketed anti-androgen drug, in pre-chemotherapy castration-resistant prostate cancer (CRPC patients).

Endorsements